GlassScriptPhysician profile
John D Corrow
NPI 1720095953
$5,093.82
in general payments reported to CMS, 2019-2025
21 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $914 · 2020: $311 · 2021: $886 · 2022: $293 · 2023: $2,075 · 2024: $371 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726 · Travel and Lodging: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,725.82 |
| Travel and Lodging | $963.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,599.93 | 2023-2024 | |
| Sight Sciences, INC. | $671.01 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $485.62 | 2019-2023 | |
| Alcon Vision LLC | $420.44 | 2019-2025 | Dailies, Tryptyr, Eysuvis |
| Sun Pharmaceutical Industries INC. | $398.03 | 2020-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $304.57 | 2021-2023 | Acuvue |
| Coopervision INC. | $276.10 | 2019-2025 | Clariti Contact Lens, Misight Contact Lens |
| Aerie Pharmaceuticals, INC. | $226.33 | 2019-2021 | |
| Visioneering Technologies, INC. | $149.10 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $143.70 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $73.50 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $55.75 | 2024 | Xdemvy |
| Abbvie INC. | $49.17 | 2023-2024 | Vuity, Lumigan |
| Katena Products, INC. (Dba Corza Medical) | $40.38 | 2019 | |
| Optos, INC. | $38.92 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $33.46 | 2022 | |
| Bausch & Lomb Americas INC. | $33.35 | 2024-2025 | Miebo, Xiidra, Infuse |
| Horizon Therapeutics Plc | $31.13 | 2023 | Tepezza |
| Astellas Pharma US INC | $26.83 | 2023 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Allergan, INC. | $17.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Corrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.